Biogen Operating Income 2010-2022 | BIIB

Biogen annual/quarterly operating income history and growth rate from 2010 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Biogen operating income for the quarter ending March 31, 2022 was $0.611B, a 37.29% decline year-over-year.
  • Biogen operating income for the twelve months ending March 31, 2022 was $2.478B, a 33.11% decline year-over-year.
  • Biogen annual operating income for 2021 was $2.841B, a 37.57% decline from 2020.
  • Biogen annual operating income for 2020 was $4.55B, a 35.39% decline from 2019.
  • Biogen annual operating income for 2019 was $7.043B, a 19.6% increase from 2018.
Biogen Annual Operating Income
(Millions of US $)
2021 $2,841
2020 $4,550
2019 $7,043
2018 $5,889
2017 $5,346
2016 $5,152
2015 $4,891
2014 $3,973
2013 $2,515
2012 $1,856
2011 $1,725
2010 $1,249
2009 $1,295
Biogen Quarterly Operating Income
(Millions of US $)
2022-03-31 $611
2021-12-31 $587
2021-09-30 $794
2021-06-30 $486
2021-03-31 $974
2020-12-31 $-331
2020-09-30 $1,086
2020-06-30 $1,975
2020-03-31 $1,820
2019-12-31 $1,778
2019-09-30 $1,806
2019-06-30 $1,956
2019-03-31 $1,503
2018-12-31 $1,443
2018-09-30 $1,698
2018-06-30 $1,213
2018-03-31 $1,535
2017-12-31 $1,466
2017-09-30 $1,654
2017-06-30 $1,201
2017-03-31 $1,025
2016-12-31 $888
2016-09-30 $1,425
2016-06-30 $1,461
2016-03-31 $1,378
2015-12-31 $1,168
2015-09-30 $1,372
2015-06-30 $1,233
2015-03-31 $1,118
2014-12-31 $1,160
2014-09-30 $1,153
2014-06-30 $989
2014-03-31 $671
2013-12-31 $658
2013-09-30 $685
2013-06-30 $663
2013-03-31 $511
2012-12-31 $446
2012-09-30 $535
2012-06-30 $506
2012-03-31 $369
2011-12-31 $409
2011-09-30 $488
2011-06-30 $411
2011-03-31 $416
2010-12-31 $355
2010-09-30 $194
2010-06-30 $396
2010-03-31 $304
2009-12-31 $383
2009-09-30 $384
2009-06-30 $223
2009-03-31 $305
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $29.239B $10.982B
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00